文献速递眼底病与葡萄膜炎

Voretigene Neparvovec治疗双等位基因RPE65突变相关遗传性视网膜病变的3至4年持久性:3期结果

Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
PubMed 文献 · Ophthalmology · 2021-03-30

结果显示,两组患者的步行导航(MLMT)、全视野光敏感阈值和视野改善均得以维持,未发生产品相关严重不良事件。

要点

  • 两组患者MLMT、全视野光敏感阈值及视野改善在3至4年随访中保持一致并维持。
  • 第3年访视时71%可完成访视的患者能在最低光照水平通过MLMT。
  • 未报告产品相关严重不良事件或有害免疫反应,安全性特征与玻璃体切割及视网膜下注射操作一致。

核心结论

  • VN注射后步行导航、光敏感和视野的改善在两组中一致,并维持至3至4年,需持续观察。
  • 安全性特征与玻璃体切割和视网膜下注射操作一致,两组间相似,未报告产品相关严重不良事件。

研究设计与样本

  • 每组各有1例在随机前或随机时退出;原干预组接受双侧视网膜下VN注射,延迟干预组先作为对照1年后接受VN。
  • 主要结局指标为双侧MLMT、全视野光敏感阈值白光、视野和视力的注射基线变化。

主要发现

  • 原干预组第4年、延迟干预组第3年的双侧MLMT平均变化评分分别为1.7和2.4,71%有第3年访视的患者能在最低光照水平通过MLMT。
  • 全视野光敏感阈值白光双眼平均变化:原干预组第4年为-1.90 log10(cd.s/m2),延迟干预组第3年为-2.91 log10(cd.s/m2)。
  • Goldmann动态视野III4e总和度数双眼平均变化:原干预组第4年为197.7,延迟干预组第3年为157.9。
  • 视力(Holladay量表)双眼平均变化:原干预组第4年为-0.003 logMAR,延迟干预组第3年为-0.06 logMAR。
  • 1例原干预组患者约在第4年发生视网膜脱离,影响了原干预组的视力;未发生产品相关严重不良事件或有害免疫反应。

临床怎么用

  • 对于双等位基因RPE65突变相关遗传性视网膜病变患者,VN治疗后步行导航、光敏感和视野改善可维持至3至4年。
  • 随访中需关注视网膜脱离等手术相关并发症,并持续观察长期疗效与安全性。

局限性

  • 原文未报告样本量以外的统计检验细节及置信区间。
  • 原文未报告各组退出者的具体原因及缺失数据处理方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether functional vision and visual function improvements after voretigene neparvovec (VN; Luxturna [Spark Therapeutics, Inc]) administration in patients with biallelic RPE65 mutation-associated inherited retinal disease are maintained at 3 to 4 years and to review safety outcomes. DESIGN: Open-label, randomized, controlled phase 3 trial. PARTICIPANTS: Thirty-one individuals were enrolled and randomized 2:1 to intervention (n = 21) or control (n = 10). One participant from each group withdrew before, or at, randomization. METHODS: Patients in the original intervention (OI) group received bilateral subretinal VN injections. Delayed intervention (DI) patients served as control participants for 1 year then received VN. MAIN OUTCOME MEASURES: Change from injection baseline in bilateral performance on the multiluminance mobility test (MLMT), a measure of ambulatory navigation, and change from injection baseline in full-field light sensitivity threshold white light, visual field (VF), and visual acuity (VA). RESULTS: Mean bilateral MLMT change scores at year 4 for OI patients and year 3 for DI patients were 1.7 and 2.4, respectively, with 71% of patients with a year 3 visit able to pass MLMT at the lowest light level. Mean change in full-field light sensitivity threshold white light, averaged over both eyes at year 4 for OI patients and year 3 for DI patients, was -1.90 log10(cd.s/m2) and -2.91 log10(cd.s/m2), respectively. Mean change in Goldmann kinetic VF III4e sum total degrees, averaged across both eyes, was 197.7 at year 4 for OI patients and 157.9 at year 3 for DI patients. Mean change in VA (Holladay scale), averaged across both eyes, was -0.003 logarithm of the minimum angle of resolution (logMAR) at year 4 for OI patients and -0.06 logMAR at year 3 for DI patients. One OI patient experienced retinal detachment at approximately year 4 that impacted VA for the OI group. No product-related serious adverse events (AEs) occurred, nor did any deleterious immune responses. CONCLUSIONS: Improvements in ambulatory navigation, light sensitivity, and VF were consistent in both intervention groups. Overall, improvements were maintained up to 3 to 4 years, with ongoing observation. The safety profile of VN was consistent with vitrectomy and the subretinal injection procedure and was similar between intervention groups, with no product-related serious AEs reported.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Maguire AM, Russell S, Chung DC, et al. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years. Ophthalmology. 2021. PMID: 33798654. doi:10.1016/j.ophtha.2021.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。